The selective MET inhibitor capmatinib has antitumor activity in patients with advanced non-small-cell lung cancer harboring MET exon 14 mutations, including in those with brain metastases, suggest GEOMETRY mono-1 study results.

Noting that capmatinib has been associated with phototoxicity in preclinical studies, the FDA advises patients to cover their skin, use sunscreen, and not tan while they are taking capmatinib.

Non-small-cell lung cancer patients with acquired resistance to epidermal growth factor receptor–tyrosine kinase inhibitor therapy and MET dysregulation could benefit from the addition of the MET inhibitor capmatinib to gefitinib, early results suggest.

Furthermore, this group comprised nine treatment-naïve individuals, 18 who had received a median 1.5 lines of prior treatment not including a MET–TKI, and 28 who had received a median 3.0 lines of treatment that included the MET–TKIs tepotinib or capmatinib.

Tejas Patil rounds up findings from the ALEX, ALTA-1L, ARROW, LIBRETTO-001, GEOMETEY mono-1 and VISION studies of non-small-cell lung cancer patients with ALK, RET, or MET alterations (9:56).

Although crizotinib was the first MET tyrosine kinase inhibitor to be evaluated in this patient group, promising data have since been reported for the more selective agents capmatinib, tepotinib, and savolitinib, say the researchers.

. © 2018 Springer Healthcare part of the Springer Nature group See also: Capmatinib–gefitinib combination has antitumor activity in MET-dysregulated NSCLC